Pharmacogenetic determinants of anti-cancer drug activity and toxicity

Trends in Pharmacological Sciences

Volumn 22, Issue 8, 2001, Pages 420-426

  Danesi, Romano ^a   De Braud, Filippo ^b   Fogli, Stefano ^a   Di Paolo, Antonello ^a   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; FLUOROURACIL; FOLIC ACID DERIVATIVE; GEMCITABINE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; NUCLEOSIDE DERIVATIVE; PACLITAXEL; PREDNISOLONE; PYRIMIDINE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; TAXANE DERIVATIVE; TIOGUANINE; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; NEUROTOXICITY; ONCOGENE; OTOTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0035425225     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01742-9     Document Type: Review

References (52)

1. Recent advances in research on multistage tumorigenesis
2. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer
3. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
4. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy
5. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer
6. Recombinant DNA and genetic techniques
7. Pharmacogenetics and the practice of medicine
8. Gene expression profiling, genetic networks, and cellular states: An integrating concept for tumorigenesis and drug discovery
9. Pharmacogenomics: Translating functional genomics into rational therapeutics
10. The impact of genomics-based technologies on drug safety evaluation
11. In vivo gene expression profile analysis of human breast cancer progression
12. Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs
13. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
14. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
15. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
16. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
17. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
18. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients
19. The Pezcoller lecture: Cancer cell cycles revisited
20. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors
21. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins
22. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma
23. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA
24. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: Association with survival and response to 5-fluorouracil in colorectal cancer
25. Pharmacogenetics of nucleoside metabolizing system in non small cell lung cancer: Implication for the chemotherapeutic efficacy of gemcitabine
26. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P
27. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
28. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
29. Apoptosis and cancer drug targeting
30. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
31. Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer
32. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
33. Bcl-xL is phosphorylated in malignant cells following microtubule disruption
34. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: A novel role for BAX during chemotherapy-induced cell death
35. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
36. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis
37. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein
38. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
39. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells
40. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
41. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
42. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
43. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
44. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)
45. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease
46. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
47. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin
48. Cytochrome P450 CYP3A in human renal cell cancer
49. Association of CYP3A4 genotype with treatment-related leukemia
50. Kinetics of arylamine N-acetyltransferase in tissues from human breast cancer
51. Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy